bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S2 from Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients
Authors: Curti Antonio , Ruggeri Loredana , Parisi Sarah , Bontadini Andrea , Dan Elisa , Motta Maria Rosa , Rizzi Simonetta , Trabanelli Sara , Ocadlikova Darina , Lecciso Mariangela , Giudice Valeria , Fruet Fiorenza , Urbani Elena , Papayannidis Cristina , Martinelli Giovanni , Bandini Giuseppe , Bonifazi Francesca , Lewis Russell E. , Cavo Michele , Velardi Andrea , Lemoli Roberto M.
Published: April 2023

Figure S2. Immunofluorescence analyses of 2 representative donor alloreactive NK cell clones expressing the KIR for which there is no class I ligand in the recipient as their only inhibitory receptor for self.
Figure S1 from Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients
Authors: Curti Antonio , Ruggeri Loredana , Parisi Sarah , Bontadini Andrea , Dan Elisa , Motta Maria Rosa , Rizzi Simonetta , Trabanelli Sara , Ocadlikova Darina , Lecciso Mariangela , Giudice Valeria , Fruet Fiorenza , Urbani Elena , Papayannidis Cristina , Martinelli Giovanni , Bandini Giuseppe , Bonifazi Francesca , Lewis Russell E. , Cavo Michele , Velardi Andrea , Lemoli Roberto M.
Published: April 2023

Figure S1. Hematologic recovery after NK cell infusion in all treated patients.
Supplementary Tables S3 from Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy
Authors: McBryan Jean , Fagan Ailís , McCartan Damian , Bane Fiona T. , Varešlija Damir , Cocchiglia Sinéad , Byrne Christopher , Bolger Jarlath , McIlroy Marie , Hudson Lance , Tibbitts Paul , Ó Gaora Peadar , Hill Arnold D. , Young Leonie S.
Published: April 2023

Supplementary Table S3: List of 21 genes which are upregulated in the metastatic liver relative to both matched primary and matched node in all three patients (where available)
Supplementary Table S2 from Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy
Authors: McBryan Jean , Fagan Ailís , McCartan Damian , Bane Fiona T. , Varešlija Damir , Cocchiglia Sinéad , Byrne Christopher , Bolger Jarlath , McIlroy Marie , Hudson Lance , Tibbitts Paul , Ó Gaora Peadar , Hill Arnold D. , Young Leonie S.
Published: April 2023

Supplementary Table S2: List of 69 genes which are downregulated in metastatic liver tumours relative to matched primary tumours for all three patients
Supplementary Table S1 from Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy
Authors: McBryan Jean , Fagan Ailís , McCartan Damian , Bane Fiona T. , Varešlija Damir , Cocchiglia Sinéad , Byrne Christopher , Bolger Jarlath , McIlroy Marie , Hudson Lance , Tibbitts Paul , Ó Gaora Peadar , Hill Arnold D. , Young Leonie S.
Published: April 2023

Supplementary Table S1: List of 31 genes which are upregulated in metastatic tumours relative to matched primary tumours for all three patients
Supplementary Figure 6 from Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell–Mediated Tumor Control in the Genital Tract
Authors: Sun Yun-Yan , Peng Shiwen , Han Liping , Qiu Jin , Song Liwen , Tsai Yachea , Yang Benjamin , Roden Richard B.S. , Trimble Cornelia L. , Hung Chien-Fu , Wu T.-C.
Published: April 2023

Analysis of HPV16 E7-specific CD8+ T cells after intracervicovaginal vaccination with or without CD4+ T cell depletion
Supplementary Figure 5 from Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell–Mediated Tumor Control in the Genital Tract
Authors: Sun Yun-Yan , Peng Shiwen , Han Liping , Qiu Jin , Song Liwen , Tsai Yachea , Yang Benjamin , Roden Richard B.S. , Trimble Cornelia L. , Hung Chien-Fu , Wu T.-C.
Published: April 2023

Comparison of anti-tumor effect generated by either pNGVL4a-Sig/E7(detox)/HSP70 intracervicovaginal vaccination followed by intracervicovaginal TA-HPV boost or intracervicovaginal TA-HPV vaccination
Supplementary Figure 4 from Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell–Mediated Tumor Control in the Genital Tract
Authors: Sun Yun-Yan , Peng Shiwen , Han Liping , Qiu Jin , Song Liwen , Tsai Yachea , Yang Benjamin , Roden Richard B.S. , Trimble Cornelia L. , Hung Chien-Fu , Wu T.-C.
Published: April 2023

Comparison of HPV16 E7-specific CD8+ T cells induced by HPV16 E7 long peptide after either intramuscular or intracervicovaginal vaccination
Supplemental Table 1 from The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine
Authors: Nawrocki Steffan T. , Kelly Kevin R. , Smith Peter G. , Keaton Mignon , Carraway Hetty , Sekeres Mikkael A. , Maciejewski Jaroslaw P. , Carew Jennifer S.
Published: April 2023

Supplemental Table 1. Clinical characteristics of AML patients who provided specimens for this study.
Supplemental Methods from The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine
Authors: Nawrocki Steffan T. , Kelly Kevin R. , Smith Peter G. , Keaton Mignon , Carraway Hetty , Sekeres Mikkael A. , Maciejewski Jaroslaw P. , Carew Jennifer S.
Published: April 2023

Supplemental Methods. Metabolomic analyses.
Supplementary Figure 1 from Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell–Mediated Tumor Control in the Genital Tract
Authors: Sun Yun-Yan , Peng Shiwen , Han Liping , Qiu Jin , Song Liwen , Tsai Yachea , Yang Benjamin , Roden Richard B.S. , Trimble Cornelia L. , Hung Chien-Fu , Wu T.-C.
Published: April 2023

Local and systemic immune responses produced by different vaccination routes
Supplementary Figure 5 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Authors: Hall Connor P. , Reynolds C. Patrick , Kang Min H.
Published: April 2023

Suppl Fig 5. MCL-1 knockdown displays limited effect on cytotoxicity and apoptosis in B-ALL model RS4;11.
Supplementary Figure 2 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Authors: Hall Connor P. , Reynolds C. Patrick , Kang Min H.
Published: April 2023

Suppl Fig 2. BEZ235, Dexamethasone, and the combination effect on cell cycle.
Supplementary Tables 1-3 from A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study
Authors: Thomas Anish , Rajan Arun , Szabo Eva , Tomita Yusuke , Carter Corey A. , Scepura Barbara , Lopez-Chavez Ariel , Lee Min-Jung , Redon Christophe E. , Frosch Ari , Peer Cody J. , Chen Yuanbin , Piekarz Richard , Steinberg Seth M. , Trepel Jane B. , Figg William D. , Schrump David S. , Giaccone Giuseppe
Published: April 2023

Table S1: Dose escalation schema; Table S2: Disease and treatment characteristics and outcomes of patients who underwent multimodality therapy; Table S3: Cycle 1 pharmacokinetic parameters of belinostat.
Supplementary Figure/Table Legends from A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study
Authors: Thomas Anish , Rajan Arun , Szabo Eva , Tomita Yusuke , Carter Corey A. , Scepura Barbara , Lopez-Chavez Ariel , Lee Min-Jung , Redon Christophe E. , Frosch Ari , Peer Cody J. , Chen Yuanbin , Piekarz Richard , Steinberg Seth M. , Trepel Jane B. , Figg William D. , Schrump David S. , Giaccone Giuseppe
Published: April 2023

Supplementary Figure/Table Legends from A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study
Supplementary Figure 2 from A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study
Authors: Thomas Anish , Rajan Arun , Szabo Eva , Tomita Yusuke , Carter Corey A. , Scepura Barbara , Lopez-Chavez Ariel , Lee Min-Jung , Redon Christophe E. , Frosch Ari , Peer Cody J. , Chen Yuanbin , Piekarz Richard , Steinberg Seth M. , Trepel Jane B. , Figg William D. , Schrump David S. , Giaccone Giuseppe
Published: April 2023

Relative changes (mean and standard deviation) in the number of CTLA4-expressing Tregs with treatment (A). Overall survival of patients with pre-treatment CTLA4 expressing-Treg numbers above and below the median (B).
Supplementary Tables and Figures from Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy
Authors: Schmidt Stefan , Linge Annett , Zwanenburg Alex , Leger Stefan , Lohaus Fabian , Krenn Constanze , Appold Steffen , Gudziol Volker , Nowak Alexander , von Neubeck Cläre , Tinhofer Inge , Budach Volker , Sak Ali , Stuschke Martin , Balermpas Panagiotis , Rödel Claus , Bunea Hatice , Grosu Anca-Ligia , Abdollahi Amir , Debus Jürgen , Ganswindt Ute , Belka Claus , Pigorsch Steffi , Combs Stephanie E. , Mönnich David , Zips Daniel , Baretton Gustavo B. , Buchholz Frank , Baumann Michael , Krause Mechthild , Löck Steffen
Published: April 2023

Table S1 Analyzed genes of the hypothesis-driven gene set. Table S2 Programs and packages used for evaluation. Figure S1 Results of repeated 3-fold cross validation for LRC. Figure S2 Mean oob ci depending of the signature size for LRC. Figure S3 Importance score for genes associated with LRC. Table S3 Increasing robustness by including highly correlated genes. Figure S4 Patient stratification by the 7-gene signature for LRC. Figure S5 Patient stratification by the 7-gene signature and clinical parameters for LRC. Table S4 Multivariable Cox regression of OS. Figure S6 Patient stratification by the 7-gene signature and clinical parameters for OS. Table S5 Multivariable Cox regression of DM. Figure S7 Patient stratification by the 7-gene signature and clinical parameters for DM. Table S6 Means and standard deviations of the 7-gene signature gene expressions. Table S7 Comparison of gene expressions between patient groups. Table S8 Hyper-parameters for feature selection algorithms and predictive models. Table S9 Patient characteristics of all patients. Figure S8 Identification of the final gene signature.
Table S1 from Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma
Authors: Krytska Kateryna , Ryles Hannah T. , Sano Renata , Raman Pichai , Infarinato Nicole R. , Hansel Theodore D. , Makena Monish R. , Song Michael M. , Reynolds C. Patrick , Mossé Yael P.
Published: April 2023

Statistical analysis of in vivo tumor growth delay and event-free survival in neuroblastoma xenografts.
Figure S4 from The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)
Authors: Vena Francesca , Li Causi Eleonora , Rodriguez-Justo Manuel , Goodstal Samantha , Hagemann Thorsten , Hartley John A. , Hochhauser Daniel
Published: April 2023

Figure S4.A. Knockdown of P53 with siRNA does not affect pimasertib-mediated RRM1 downregulation. Figure S4.B. Reduction of RRM1 protein induced by MEK inhibition is mediated by AKT.
Figure S1 from Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan
Authors: Coghill Anna E. , Pfeiffer Ruth M. , Proietti Carla , Hsu Wan-Lun , Chien Yin-Chu , Lekieffre Lea , Krause Lutz , Teng Andy , Pablo Jocelyn , Yu Kelly J. , Lou Pei-Jen , Wang Cheng-Ping , Liu Zhiwei , Chen Chien-Jen , Middeldorp Jaap , Mulvenna Jason , Bethony Jeff , Hildesheim Allan , Doolan Denise L.
Published: April 2023

Percent sequence identity of 10 Chinese strains with protein sequences printed on the microarray
EBV viral load in myeloma patients receiving LTD, comparing baseline to first and final cycle of therapy. from Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression
Authors: Jones Richard J. , Iempridee Tawin , Wang Xiaobin , Lee Hans C. , Mertz Janet E. , Kenney Shannon C. , Lin Heather C. , Baladandayuthapani Veerabhadran , Dawson Christopher W. , Shah Jatin J. , Weber Donna M. , Orlowski Robert Z.
Published: April 2023

EBV viral loads in patient serum samples on a LEN, THAL, DEX combination.
Supplemental Figure 3 from A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma
Authors: Galloway Thomas J. , Wirth Lori J. , Colevas Alexander D. , Gilbert Jill , Bauman Julie E. , Saba Nabil F. , Raben David , Mehra Ranee , Ma Anna W. , Atoyan Ruzanna , Wang Jing , Burtness Barbara , Jimeno Antonio
Published: April 2023

Supplemental Figure 3. Ac-H3 induction in PBMCs from patients with evaluable clinical response.
Supplement from Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Authors: Strauss Julius , Heery Christopher R. , Schlom Jeffrey , Madan Ravi A. , Cao Liang , Kang Zhigang , Lamping Elizabeth , Marté Jennifer L. , Donahue Renee N. , Grenga Italia , Cordes Lisa , Christensen Olaf , Mahnke Lisa , Helwig Christoph , Gulley James L.
Published: April 2023

Supplementary Table 1. Serious Adverse Events Supplementary Table 2. Treatment-Related Serious Adverse Events Supplementary Table 3. Treatment-Related Adverse Events Occurring During the Dose-Limiting Toxicity Assessment Window Supplementary Table 4: All Adverse Events That Were Either Grade {greater than or equal to}3 or Occurred in >1 Patient Supplementary Figure 1A: This 57-year-old woman with anal cancer metastatic to liver and retroperitoneal and periportal nodes had progressive disease at enrollment. Restaging scans at 3 months showed a PR, which was confirmed at 4.5 months. Supplementary Figure 1B: CEA curve for patient with anal cancer with an ongoing durable confirmed PR. Supplementary Figure 1C: This 56-year-old woman with locally advanced cervical cancer s/p cisplatin/RT with metastases to lung within 3 months of initial treatment s/p topotecan/taxol plus bevacizumab was enrolled with enlarging right-sided lung masses. Restaging at 12 weeks showed a marked reduction in disease volume.
Supplementary Table 1 from Polymorphisms of Asparaginase Pathway and Asparaginase-Related Complications in Children with Acute Lymphoblastic Leukemia
Authors: Ben Tanfous Mohsen , Sharif-Askari Bahram , Ceppi Francesco , Laaribi Haithem , Gagné Vincent , Rousseau Julie , Labuda Malgorzata , Silverman Lewis B. , Sallan Stephen E. , Neuberg Donna , Kutok Jeffery L. , Sinnett Daniel , Laverdière Caroline , Krajinovic Maja
Published: April 2023

PDF file - 80K, Polymorphisms in ATF5, ASNS and ASS1 genes analyzed in the relation to ASNase related complications.
Supplementary Table S2 from A Novel CDC25B Promoter–Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models
Authors: Weber Helga L. , Gidekel Manuel , Werbajh Santiago , Salvatierra Edgardo , Rotondaro Cecilia , Sganga Leonardo , Haab Gabriela Acosta , Curiel David T. , Cafferata Eduardo G. , Podhajcer Osvaldo L.
Published: April 2023

Supplementary Table S2. Synergy between AV25CDC and GEM therapy on pancreatic cancer xenograft
Supplementary Tables S1-S3, Figures S1-S2 from Cross-Species Antibody Microarray Interrogation Identifies a 3-Protein Panel of Plasma Biomarkers for Early Diagnosis of Pancreas Cancer
Authors: Mirus Justin E. , Zhang Yuzheng , Li Christopher I. , Lokshin Anna E. , Prentice Ross L. , Hingorani Sunil R. , Lampe Paul D.
Published: April 2023

Supplementary Tables S1-S3, Figures S1-S2. Supplementary Table S1: Candidate biomarkers for KPC preinvasive and invasive plasma drawn between 8-10 weeks and midway through disease progression, respectively. Supplementary Table S2: Candidate down-regulated plasma biomarkers from analysis of WHI pre-diagnostic plasma antibody microarray interrogation. Supplementary Table S3: A comparison of receiver operator characteristic (ROC) area under the curve values for the 3-marker panel of ESR1, ERBB2 and TNC in pre-diagnostic plasma to those for previously reported serum and plasma biomarkers discovered in diagnostic plasma samples. Supplementary Figure S1: Plasma M-values for TNC, ERBB2 and ESR1 do not show significant change as the time between blood draw and death decreases. Supplementary Figure S2: Dot plot of individual case and control diagnostic plasma composite values for (A) 3 marker panel (TNC, ERBB2 and ESR1) and (B) 3 marker panel plus CA19-9. Mean and standard deviations are indicated.
Supplementary Table S1 from A Novel CDC25B Promoter–Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models
Authors: Weber Helga L. , Gidekel Manuel , Werbajh Santiago , Salvatierra Edgardo , Rotondaro Cecilia , Sganga Leonardo , Haab Gabriela Acosta , Curiel David T. , Cafferata Eduardo G. , Podhajcer Osvaldo L.
Published: April 2023

Supplementary Table S1. CDC25B gene expression in different cell types
Supplementary Table 2 from Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer
Authors: Alagesan Brinda , Contino Gianmarco , Guimaraes Alexander R. , Corcoran Ryan B. , Deshpande Vikram , Wojtkiewicz Gregory R. , Hezel Aram F. , Wong Kwok-Kin , Loda Massimo , Weissleder Ralph , Benes Cyril , Engelman Jeffrey A. , Bardeesy Nabeel
Published: April 2023

Supplementary Table 2. Excel spreadsheet showing results of drug screen indicating sensitivity of PDA cell lines across a range of drug concentrations.
Supplementary Figure S2 from A Novel CDC25B Promoter–Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models
Authors: Weber Helga L. , Gidekel Manuel , Werbajh Santiago , Salvatierra Edgardo , Rotondaro Cecilia , Sganga Leonardo , Haab Gabriela Acosta , Curiel David T. , Cafferata Eduardo G. , Podhajcer Osvaldo L.
Published: April 2023

Supplementary Figure S2. Efficacy of AV25CDC on hamster pancreatic cells and orthotopic tumors in combination with Gemcitabine
Supplementary Figure S1 from A Novel CDC25B Promoter–Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models
Authors: Weber Helga L. , Gidekel Manuel , Werbajh Santiago , Salvatierra Edgardo , Rotondaro Cecilia , Sganga Leonardo , Haab Gabriela Acosta , Curiel David T. , Cafferata Eduardo G. , Podhajcer Osvaldo L.
Published: April 2023

Supplementary Figure S1. Schematic representation of fragment of the human CDC25 promoter and In vitro and in vivo efficacy of AV25CDC in combination or not with gemcitabine.
Supplementary figure legend from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib
Authors: Nilsson Monique B. , Giri Uma , Gudikote Jayanthi , Tang Ximing , Lu Wei , Tran Hai , Fan Youhong , Koo Andrew , Diao Lixia , Tong Pan , Wang Jing , Herbst Roy , Johnson Bruce E. , Ryan Andy , Webster Alan , Rowe Philip , Wistuba Ignacio I. , Heymach John V.
Published: April 2023

Supplementary figure legend
Supplementary Figure S1 and Supplementary Tables S1-S2 from Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay
Authors: Prat Aleix , Galván Patricia , Jimenez Begoña , Buckingham Wesley , Jeiranian H. Arthur , Schaper Carl , Vidal Maria , Álvarez Martina , Díaz Sherley , Ellis Catherine , Nuciforo Paolo , Ferree Sean , Ribelles Nuria , Adamo Barbara , Ramón y Cajal Santiago , Peg Vicente , Alba Emilio
Published: April 2023

Supplementary Figure S1 and Supplementary Tables S1-S2. Supplementary Figure S1. Diagram of tissue block usage for CNB Development Study and Chemo-prediction Validation Study. Supplemental Table S1. Top-10 and bottom-10 Prosigna gene-correlations between paired CNBs and SRS. Supplemental Table S2. Distribution of the Prosigna subtypes within the three main pathology-based groups in 39 independent metastatic samples.
Supplementary Tables 1-2, Figures 1-4 from Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)
Authors: Cushman Stephanie M. , Jiang Chen , Hatch Ace J. , Shterev Ivo , Sibley Alexander B. , Niedzwiecki Donna , Venook Alan P. , Owzar Kouros , Hurwitz Herbert I. , Nixon Andrew B.
Published: April 2023

Supplementary Tables 1-2, Figures 1-4. Supplementary Table 1: List of assay primer sets used in this study. Supplementary Table 2. Table of co-regulation among the 14 genes using a Kendall tau analysis. Supplementary Figure 1: Forest plots showing associations of gene expression levels with OS in KRAS WT (A) and KRAS Mut (B) pts. All assayed genes are shown. Supplementary Figure 2: Forest plots showing associations of gene expression levels with PFS in KRAS WT (A) and KRAS Mut (B) pts. Supplementary Figure 3: Forest plots showing associations of gene expression levels and treatment group with OS in KRAS WT (A) and KRAS Mut (B) pts. Supplementary Figure 4: Forest plots showing associations of gene expression levels and treatment group with PFS in KRAS WT (A) and KRAS Mut (B) pts. All assayed genes are shown.
Supplementary Figure 1 from Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Authors: Humbert Olivier , Riedinger Jean-Marc , Charon-Barra Céline , Berriolo-Riedinger Alina , Desmoulins Isabelle , Lorgis Véronique , Kanoun Salim , Coutant Charles , Fumoleau Pierre , Cochet Alexandre , Brunotte François
Published: April 2023

Supplementary Figure 1: Graphical display of changes in primary tumor SUVmax between baseline and interim 18F-FDG PET exams.
Supplementary Figure 2. Confirmation that RET mediates GFRα1 effects in prostate cancer using a second siRNA. from RET Signaling in Prostate Cancer
Authors: Ban Kechen , Feng Shu , Shao Longjiang , Ittmann Michael
Published: April 2023

A. Knockdown of RET mRNA by RET siRNA in LNCaP and 22RV1 cells. B-D. Effect of RET siRNA on GFRα1 induced proliferation (B), invasion (C) and soft agar colony formation (D). The p-values for significant differences by t-test are shown.
Supplementary Table 2. from KIT Exon 11 Codons 557–558 Deletion Mutation Promotes Liver Metastasis Through the CXCL12/CXCR4 Axis in Gastrointestinal Stromal Tumors
Authors: Wang Hao-Chen , Li Tzu-Ying , Chao Ying-Jui , Hou Ya-Chin , Hsueh Yuan-Shuo , Hsu Kai-Hsi , Shan Yan-Shen
Published: April 2023

List of antibodies
Supplementary Table 1. from KIT Exon 11 Codons 557–558 Deletion Mutation Promotes Liver Metastasis Through the CXCL12/CXCR4 Axis in Gastrointestinal Stromal Tumors
Authors: Wang Hao-Chen , Li Tzu-Ying , Chao Ying-Jui , Hou Ya-Chin , Hsueh Yuan-Shuo , Hsu Kai-Hsi , Shan Yan-Shen
Published: April 2023

KIT and PDGFRα mutation types in primary GISTs with respect to liver metastasis
Supplementary Data from Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition
Authors: Rizq Ola , Mimura Naoya , Oshima Motohiko , Saraya Atsunori , Koide Shuhei , Kato Yuko , Aoyama Kazumasa , Nakajima-Takagi Yaeko , Wang Changshan , Chiba Tetsuhiro , Ma Anqi , Jin Jian , Iseki Tohru , Nakaseko Chiaki , Iwama Atsushi
Published: April 2023

Supplementary Materials and Methods Supplementary References Supplementary Tables Supplementary Figures and legends Supplementary Table S1 Combination index (CI) values. Supplementary Table S2 Significantly upregulated PRC2 gene sets in UNC1999-treated MM.1S cells (FDR q-value < 0.05) Supplementary Table S3 Significantly upregulated PRC2 gene sets in combination-treated MM.1S cells (FDR q-value < 0.05) Supplementary Table S4 Top 74 PRC2 genes that are significantly altered in UNC1999-treated MM.1S cells Supplementary Table S5 Significantly upregulated gene sets in RPMI8226 cells transduced with EZH2- overexpressing versus empty vectors. Supplementary Table S6 List of primers used for Quantitative RT-PCR Supplementary Table S7 List of primers used for ChIP-PCR Supplementary Figure S1. Pharmacological and lentiviral suppression of EZH2 and EZH1 in MM cell lines. Supplementary Figure S2. Proteasome inhibitors downregulate EZH2 in MM cell lines. Supplementary Figure S3. EZH2 suppression by bortezomib is mediated through E2F1. Supplementary Figure S4. MM patients with higher levels of EZH2 expression have poorer response to bortezomib. Supplementary Figure S5. EZH2 overexpression in MM cells confers resistance to bortezomib through upregulation of gene sets related to MYC, cell cycle and metabolism. Supplementary Figure S6. UNC1999 enhances the cytotoxicity induced by bortezomib in MM cell lines including resistant ones but not in PBMNCs from healthy donors. Supplementary Figure S7. The combination of UNC1999 and bortezomib induces significant apoptosis in vitro and is tolerated in vivo. Supplementary Figure S8. The expression of NR4As in MM. Supplementary Figure S9. Dual inhibition of EZH2 and EZH1, but not specific EZH2 inhibition, is critical for the synergy with bortezomib in MM cell lines. Supplementary Figure S10. UNC1999 exhibits synergy with bortezomib in DU145 prostate cancer cells.
Supplementary Methods from Neural Stem Cell–Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients
Authors: Portnow Jana , Synold Timothy W. , Badie Behnam , Tirughana Revathiswari , Lacey Simon F. , D'Apuzzo Massimo , Metz Marianne Z. , Najbauer Joseph , Bedell Victoria , Vo Tien , Gutova Margarita , Frankel Paul , Chen Mike , Aboody Karen S.
Published: April 2023

Supplementary Methods from Neural Stem Cell–Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients
Supplementary materials from Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
Authors: Hu Yongxian , Wu Zhao , Luo Yi , Shi Jimin , Yu Jian , Pu Chengfei , Liang Zuyu , Wei Guoqing , Cui Qu , Sun Jie , Jiang Jing , Xie Jue , Tan Yamin , Ni Wanmao , Tu Jifang , Wang Jinping , Jin Aiyun , Zhang Hao , Cai Zhen , Xiao Lei , Huang He
Published: April 2023

Supplementary materials
Figure S5 from Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity
Authors: Oizel Kristell , Chauvin Cynthia , Oliver Lisa , Gratas Catherine , Geraldo Fanny , Jarry Ulrich , Scotet Emmanuel , Rabe Marion , Alves-Guerra Marie-Clotilde , Teusan Raluca , Gautier Fabien , Loussouarn Delphine , Compan Vincent , Martinou Jean-Claude , Vallette François M. , Pecqueur Claire
Published: April 2023

Glutamine metabolism inhibitors in U87 cells
Supplementary Figure 3 from Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
Authors: Hu Yongxian , Wu Zhao , Luo Yi , Shi Jimin , Yu Jian , Pu Chengfei , Liang Zuyu , Wei Guoqing , Cui Qu , Sun Jie , Jiang Jing , Xie Jue , Tan Yamin , Ni Wanmao , Tu Jifang , Wang Jinping , Jin Aiyun , Zhang Hao , Cai Zhen , Xiao Lei , Huang He
Published: April 2023

Patient 13 with extramedullary leukemia relapse compromising testis obtained CR after CART19 infusion. A, Ultrasound showed complete elimination of extramedullary relapsed masses involved in testis (red arrows). Images are from before treatment and 90 days after CART19 infusion. B, Pathology showed complete elimination of extramedullary relapsed masses involved in testis. Images are from before treatment and 30 days after CART19 infusion. Left: 10Ã—10, right: 10Ã—40.
Supplementary Figure 1 from Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
Authors: Hu Yongxian , Wu Zhao , Luo Yi , Shi Jimin , Yu Jian , Pu Chengfei , Liang Zuyu , Wei Guoqing , Cui Qu , Sun Jie , Jiang Jing , Xie Jue , Tan Yamin , Ni Wanmao , Tu Jifang , Wang Jinping , Jin Aiyun , Zhang Hao , Cai Zhen , Xiao Lei , Huang He
Published: April 2023

CART19 identification and quantification
Treatment Exposure from Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response
Authors: Schneider Bryan J. , Shah Manish A. , Klute Kelsey , Ocean Allyson , Popa Elizabeta , Altorki Nasser , Lieberman Michael , Schreiner Andrew , Yantiss Rhonda , Christos Paul J. , Palmer Romae , You Daoqi , Viale Agnes , Kermani Pouneh , Scandura Joseph M.
Published: April 2023

Treatment Exposure
Supplementary Table from Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
Authors: Bihani Teeru , Patel Hitisha K. , Arlt Heike , Tao Nianjun , Jiang Hai , Brown Jeffrey L. , Purandare Dinesh M. , Hattersley Gary , Garner Fiona
Published: April 2023

Supplementary Table
EOX Dose Modifications from Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response
Authors: Schneider Bryan J. , Shah Manish A. , Klute Kelsey , Ocean Allyson , Popa Elizabeta , Altorki Nasser , Lieberman Michael , Schreiner Andrew , Yantiss Rhonda , Christos Paul J. , Palmer Romae , You Daoqi , Viale Agnes , Kermani Pouneh , Scandura Joseph M.
Published: April 2023

EOX Dose Modifications
Supplementary Figures from Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
Authors: Bihani Teeru , Patel Hitisha K. , Arlt Heike , Tao Nianjun , Jiang Hai , Brown Jeffrey L. , Purandare Dinesh M. , Hattersley Gary , Garner Fiona
Published: April 2023

Supplementary Figures
Supplementary Legend from Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space
Authors: Wood Oliver , Clarke James , Woo Jeongmin , Mirza Adal H. , Woelk Christopher H. , Thomas Gareth J. , Vijayanand Pandurangan , King Emma , Ottensmeier Christian H.
Published: April 2023

Supplementary Legend
Table S3 from Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition
Authors: Ketola Kirsi , Munuganti Ravi S.N. , Davies Alastair , Nip Ka Mun , Bishop Jennifer L. , Zoubeidi Amina
Published: April 2023

Supplementary Table S3. Up and downregulated genes in response to Mon in 42DENZR cells assessed by gene expression profiling.
Supplemental Table 2 from Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial
Authors: Mohrbacher Ann M. , Yang Allen S. , Groshen Susan , Kummar Shivaani , Gutierrez Martin E. , Kang Min H. , Tsao-Wei Denice , Reynolds C. Patrick , Newman Edward M. , Maurer Barry J.
Published: April 2023

Patient diagnosis, courses received, best response
Table S2 from Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition
Authors: Ketola Kirsi , Munuganti Ravi S.N. , Davies Alastair , Nip Ka Mun , Bishop Jennifer L. , Zoubeidi Amina
Published: April 2023

Supplementary Table S2. Cox regression analyses of FOXM1 as a prognostic factor for patients
Supplementary Figures Legends Clean from Personalized Medicine–Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids
Authors: Raghavan Shreya , Mehta Pooja , Ward Maria R. , Bregenzer Michael E. , Fleck Elyse M. A. , Tan Lijun , McLean Karen , Buckanovich Ronald J. , Mehta Geeta
Published: April 2023

Supplementary Figures Legends
Supplementary Figure 5 from Personalized Medicine–Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids
Authors: Raghavan Shreya , Mehta Pooja , Ward Maria R. , Bregenzer Michael E. , Fleck Elyse M. A. , Tan Lijun , McLean Karen , Buckanovich Ronald J. , Mehta Geeta
Published: April 2023

Supplementary Figure 5: Flow cytometry analysis of Pt259 OvCSC spheroids treated with cisplatin, compound 673A or ruxolitinib
Supplemental R File 2-MDACC TMA from Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer
Authors: Hunt Kelly K. , Karakas Cansu , Ha Min Jin , Biernacka Anna , Yi Min , Sahin Aysegul A. , Adjapong Opoku , Hortobagyi Gabriel N. , Bondy Melissa L. , Thompson Patricia A. , Cheung Kwok Leung , Ellis Ian O. , Bacus Sarah , Symmans W. Fraser , Do Kim-Anh , Keyomarsi Khandan
Published: April 2023

R File codes pertaining to the MDACC-TMA cohort
Supplementary Figure 3 from Personalized Medicine–Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids
Authors: Raghavan Shreya , Mehta Pooja , Ward Maria R. , Bregenzer Michael E. , Fleck Elyse M. A. , Tan Lijun , McLean Karen , Buckanovich Ronald J. , Mehta Geeta
Published: April 2023

Supplementary Figure 3: Drug dose response of cisplatin, 673A, and ruxolitinib on Pt259 OvCSC spheroids
Supplemental Data from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Authors: Krejcik Jakub , Frerichs Kris A. , Nijhof Inger S. , van Kessel Berris , van Velzen Jeroen F. , Bloem Andries C. , Broekmans Marloes E.C. , Zweegman Sonja , van Meerloo Johan , Musters René J.P. , Poddighe Pino J. , Groen Richard W.J. , Chiu Christopher , Plesner Torben , Lokhorst Henk M. , Sasser A. Kate , Mutis Tuna , van de Donk Niels W.C.J.
Published: April 2023

Supplemental Methods, Supplementary Tables, Supplementary Figure Legends
Figure S3 from Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor–Modified T Cells Engineered to Secrete Checkpoint Inhibitors
Authors: Li Si , Siriwon Natnaree , Zhang Xiaoyang , Yang Shuai , Jin Tao , He Feng , Kim Yu Jeong , Mac John , Lu Zhengfei , Wang Sijie , Han Xiaolu , Wang Pin
Published: April 2023

Population doublings of nontransduced (NT), CAR19 and CAR19.Î±PD1 T cells upon antigen-specific stimulation for 3 days (n = 3, mean {plus minus} SEM; **P<0.01).
Supplementary Table S2 from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
Authors: Hahn Noah M. , Bivalacqua Trinity J. , Ross Ashley E. , Netto George J. , Baras Alex , Park Jong Chul , Chapman Carolyn , Masterson Timothy A. , Koch Michael O. , Bihrle Richard , Foster Richard S. , Gardner Thomas A. , Cheng Liang , Jones David R. , McElyea Kyle , Sandusky George E. , Breen Timothy , Liu Ziyue , Albany Costantine , Moore Marietta L. , Loman Rhoda L. , Reed Angela , Turner Scott A. , De Abreu Francine B. , Gallagher Torrey , Tsongalis Gregory J. , Plimack Elizabeth R. , Greenberg Richard E. , Geynisman Daniel M.
Published: April 2023

Supplementary Table S2: Cystectomy Pathologic Staging
Supplementary Table 3 from Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma
Authors: Mouw Kent W. , Cleary James M. , Reardon Brendan , Pike Jonathan , Braunstein Lior Z. , Kim Jaegil , Amin-Mansour Ali , Miao Diana , Damish Alexis , Chin Joanna , Ott Patrick A. , Fuchs Charles S. , Martin Neil E. , Getz Gad , Carter Scott , Mamon Harvey J. , Hornick Jason L. , Van Allen Eliezer M. , D'Andrea Alan D.
Published: April 2023

Supplementary Table 3
Supplementary Information from Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma
Authors: Mouw Kent W. , Cleary James M. , Reardon Brendan , Pike Jonathan , Braunstein Lior Z. , Kim Jaegil , Amin-Mansour Ali , Miao Diana , Damish Alexis , Chin Joanna , Ott Patrick A. , Fuchs Charles S. , Martin Neil E. , Getz Gad , Carter Scott , Mamon Harvey J. , Hornick Jason L. , Van Allen Eliezer M. , D'Andrea Alan D.
Published: April 2023

Supplementary Methods, Tables, and Figures
Supplementary Figure S1 from Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia
Authors: Jin Bei , Wang Chengyan , Li Juan , Du Xin , Ding Ke , Pan Jingxuan
Published: April 2023

NF-κB positively regulates the expression and nucleus translocation of FOXM1 and β-catenin.
Supplementary Figures from STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma
Authors: Otaka Yukihiro , Rokudai Susumu , Kaira Kyoichi , Fujieda Michiru , Horikoshi Ikuko , Iwakawa-Kawabata Reika , Yoshiyama Shinji , Yokobori Takehiko , Ohtaki Yoichi , Shimizu Kimihiro , Oyama Tetsunari , Tamura Jun'ichi , Prives Carol , Nishiyama Masahiko
Published: April 2023

Supplementary Figure 1. STXBP4 expression is correlated with poor prognosis in patients with tumors expressing high Î”Np63 levels. Supplementary Figure 2. Causal networks associated with STXBP4 expression in lung SCC. Supplementary Figure 3. Depletion of PDGFRÎ± suppresses the growth of lung SCC. Supplementary Figure 4. PDGFRA mRNA was significantly correlated with STXBP4 in the gene expression profiles of lung SCC patients. Supplementary Figure 5. PDGFRA expression is upregulated in STXBP4-transduced lung SCC cells. Supplementary Figure 6. STXBP4-depletion inhibits SCC tumorigenesis and modulates PDGF signaling in vivo. Supplementary Figure 7. STXBP4 promotes tumorigenesis through PDGFRA in lung SCC.
Figure S2 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
Authors: Yi John S. , Ready Neal , Healy Patrick , Dumbauld Chelsae , Osborne Robyn , Berry Mark , Shoemaker Debra , Clarke Jeffrey , Crawford Jeffrey , Tong Betty , Harpole David , D'Amico Thomas A. , McSherry Frances , Dunphy Frank , McCall Shannon J. , Christensen Jared D. , Wang Xiaofei , Weinhold Kent J.
Published: April 2023

Spaghetti plots of MDSC and Tregs by visits; stratified by overall response.
Figure S4 from Aspirin Inhibits Cancer Metastasis and Angiogenesis via Targeting Heparanase
Authors: Dai Xiaoyang , Yan Juan , Fu Xuhong , Pan Qiuming , Sun Danni , Xu Yuan , Wang Jiang , Nie Litong , Tong Linjiang , Shen Aijun , Zheng Mingyue , Huang Min , Tan Minjia , Liu Hong , Huang Xun , Ding Jian , Geng Meiyu
Published: April 2023

supplementary Figure S4 shows the inhibition effect of aspirin on tube formation of HUVEC
Figure S2 from Aspirin Inhibits Cancer Metastasis and Angiogenesis via Targeting Heparanase
Authors: Dai Xiaoyang , Yan Juan , Fu Xuhong , Pan Qiuming , Sun Danni , Xu Yuan , Wang Jiang , Nie Litong , Tong Linjiang , Shen Aijun , Zheng Mingyue , Huang Min , Tan Minjia , Liu Hong , Huang Xun , Ding Jian , Geng Meiyu
Published: April 2023

supplementaty Figure S2 shows the inhibitory effect of aspirin and salicylic acid on degradation of heparan sulfate by heparanase
Supplementary Table S4 from A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors
Authors: Yam Clinton , Xu Xiaowei , Davies Michael A. , Gimotty Phyllis A. , Morrissette Jennifer J.D. , Tetzlaff Michael T. , Wani Khalida M. , Liu Shujing , Deng Wanleng , Buckley Meghan , Zhao Jianhua , Amaravadi Ravi K. , Haas Naomi B. , Kudchadkar Ragini R. , Pavlick Anna C. , Sosman Jeffrey A. , Tawbi Hussein , Walker Luke , Schuchter Lynn M. , Karakousis Giorgos C. , Gangadhar Tara C.
Published: April 2023

Patterns of progression. A table summarizing the patterns of progression for patients (N=14) who had progression of disease by RECIST v1.1 criteria while on this study.
Supplementary Table 2 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
Authors: Ritthipichai Krit , Haymaker Cara L. , Martinez Melisa , Aschenbrenner Andrew , Yi Xiaohui , Zhang Minying , Kale Charuta , Vence Luis M. , Roszik Jason , Hailemichael Yared , Overwijk Willem W. , Varadarajan Navin , Nurieva Roza , Radvanyi Laszlo G. , Hwu Patrick , Bernatchez Chantale
Published: April 2023

Modifications to the BTLA sequence introduced to generate the variants used in this study are shown in red.
Sup. Fig 6 from Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia
Authors: Budhraja Amit , Turnis Meghan E. , Churchman Michelle L. , Kothari Anisha , Yang Xue , Xu Haiyan , Kaminska Ewa , Panetta John C. , Finkelstein David , Mullighan Charles G. , Opferman Joseph T.
Published: April 2023

Pathology of DHA and ABT-263 treatment in mice
Sup Figure Legends and Methods from Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia
Authors: Budhraja Amit , Turnis Meghan E. , Churchman Michelle L. , Kothari Anisha , Yang Xue , Xu Haiyan , Kaminska Ewa , Panetta John C. , Finkelstein David , Mullighan Charles G. , Opferman Joseph T.
Published: April 2023

Methods and Figure Legends for Supplement
Supplementary figure legend and tables from Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients
Authors: Brand Judith S. , Hedayati Elham , Humphreys Keith , Ludvigsson Jonas F. , Johansson Anna L.V. , Bergh Jonas , Hall Per , Czene Kamila
Published: April 2023

Supplementary Figure 1 legend, Supplementary Tables 1-7. Supplementary Figure 1 legend. Supplementary Table 1. ICD codes for venous thromboembolism. Supplementary Table 2. Single nucleotide polymorphisms included in the VTE polygenic risk score. Supplementary Table 3. Patient, tumor and treatment characteristics of the study population. Supplementary Table 4. Chemotherapy and VTE risk in breast cancer patients - analyses by chemotherapy agent and stratified by endocrine therapy. Supplementary Table 5. Venous thromboembolism risk in breast cancer patients by chemotherapy and FVL carriership. Supplementary Table 6. Hazard ratios for venous thromboembolism in breast cancer patients by chemotherapy and genetic susceptibility - sensitivity analyses. Supplementary Table 7. Cumulative incidences of VTE by chemotherapy and genetic susceptibility - sensitivity analyses.
Supplemental Figure 1 from Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib
Authors: Amengual Jennifer E. , Prabhu Sathyen A. , Lombardo Maximilian , Zullo Kelly , Johannet Paul M. , Gonzalez Yulissa , Scotto Luigi , Serrano Xavier Jirau , Wei Ying , Duong Jimmy , Nandakumar Renu , Cremers Serge , Verma Akanksha , Elemento Olivier , O'Connor Owen A.
Published: April 2023

Standard error values for ACY-1215 plus ibrutinib combinations in cell lines and primary human lymphoma samples. Viability was measured by CellTiter-Glo. Each experiment was performed in triplicate and repeated at least 2 times. The standard error was calculated for each (a) cell line and (b) primary human lymphoma sample for each time point and drug concentration. The tables represented here correspond to the experiments in Figure 4a and 4b.
Supplementary figure 3 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Authors: He Xiao-yan , Tan Zheng-lan , Mou Qin , Liu Fang-jie , Liu Shan , Yu Chao-wen , Zhu Jin , Lv Lin-ya , Zhang Jun , Wang Shan , Bao Li-ming , Peng Bin , Zhao Hui , Zou Lin
Published: April 2023

miR-221 expression in NB cells and tumor xenografts.
Copyright Transfer from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Authors: He Xiao-yan , Tan Zheng-lan , Mou Qin , Liu Fang-jie , Liu Shan , Yu Chao-wen , Zhu Jin , Lv Lin-ya , Zhang Jun , Wang Shan , Bao Li-ming , Peng Bin , Zhao Hui , Zou Lin
Published: April 2023

Conflict of Interest Form
Table S1 from Ex Vivo PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients
Authors: Chen Yuan , Xue Shao-An , Behboudi Shahriar , Mohammad Goran H. , Pereira Stephen P. , Morris Emma C.
Published: April 2023

We initially investigated antigen-specific CTL responses generated upon short-term culture of T cells from PBMCs of 13 PC patients (supplemental table S1) and 10 healthy controls upon stimulation with 3 CEA HLA-A2-restricted peptides (CEA605-613 YLSGANLNL, CEA691-699 IMIGVLVGV, and CEA694-702 GVLVGVALI) as well as one irrelevant peptide Telomerase540-548 ILAKFLHWL by short-term cultures (9-10 days). This table shows the clinical information of the 13 PC patients. Antigen-specific IFN-γ producing CD8 T cells responses are shown in Supplemental Figure S1.
Conflict Disclosure from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Authors: He Xiao-yan , Tan Zheng-lan , Mou Qin , Liu Fang-jie , Liu Shan , Yu Chao-wen , Zhu Jin , Lv Lin-ya , Zhang Jun , Wang Shan , Bao Li-ming , Peng Bin , Zhao Hui , Zou Lin
Published: April 2023

Conflict of Interest Form
Table S1 from The NOTCH4–HEY1 Pathway Induces Epithelial–Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma
Authors: Fukusumi Takahito , Guo Theresa W. , Sakai Akihiro , Ando Mizuo , Ren Shuling , Haft Sunny , Liu Chao , Amornphimoltham Panomwat , Gutkind J. Silvio , Califano Joseph A.
Published: April 2023

Table S1. HNSCC NOTCH mutation samples in TCGA
Supplementary Figure 2 from Neoadjuvant Enzalutamide Prior to Prostatectomy
Authors: Montgomery Bruce , Tretiakova Maria S. , Joshua Anthony M. , Gleave Martin E. , Fleshner Neil , Bubley Glenn J. , Mostaghel Elahe A. , Chi Kim N. , Lin Daniel W. , Sanda Martin , Novotny William , Wu Kenneth , Kantoff Philip W. , Marck Brett T. , Plymate Stephen , Balk Steven P. , Nelson Peter S. , Matsumoto Alvin M. , Lis Rosina T. , Kibel Adam , Haas Gabriel P. , Krivoshik Andrew , Hannah Alison , Taplin Mary-Ellen
Published: April 2023

Prostate androgen levels after enza or enza/dut/LHRHa. Tissue androgens from prostatectomy specimens after 6 months of therapy were measured by mass spectroscopy to determine levels of (A) pregnenolone, (B) progesterone, (C) DHEA, (D) AED, (E) testosterone, and (F) DHT. P values were calculated using the nonparametric Mann-Whitney test. Limits of quantification were 0.015 pg/mg for AED, progesterone, and testosterone, 0.03 pg/mg for DHT and pregnenolone, and 0.49 pg/mg for DHEA.
Figure S6 from The NOTCH4–HEY1 Pathway Induces Epithelial–Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma
Authors: Fukusumi Takahito , Guo Theresa W. , Sakai Akihiro , Ando Mizuo , Ren Shuling , Haft Sunny , Liu Chao , Amornphimoltham Panomwat , Gutkind J. Silvio , Califano Joseph A.
Published: April 2023

Figure S6. Comparison of overall survival between NOTCH4, HEY1 high and low groups using the TCGA data set.